Course InformationTherapautic Area: Cardiology
Credit(s): 2.00 AMA PRA Category 1 Credit(s)™
Activity Dates: December 29, 2016 - December 28, 2017
This activity will focus on the most current clinical trial data for achieving LDL-C goal for all patients in the era of PCSK9 inhibitors as presented as an Unofficial Satellite Event at the American Heart Association Scientific Sessions 2016. The expert faculty utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision-making. The educational material of this symposium will provide information that every cardiologists needs to know to improve healthcare outcomes in their patients with cardiovascular disease.
Cardiologists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.
- Review the science of PCSK9 inhibitors for patients with dyslipidemia.
- Analyze extended clinical trial data for PCSK9 inhibitors.
- Formulate personalized treatment plans to incorporate PCSK9 inhibitors to reduce risk and improve outcomes for patients with dyslipidemia.
Christopher P. Cannon, MD
Professor of Medicine
Harvard Medical School
Executive Director, Cardiometabolic Trials
Baim Institute for Clinical Research
Senior Physician, Cardiovascular Division
Brigham and Women’s Hospital
Christie M. Ballantyne, MD
Professor of Medicine
Baylor College of Medicine
Center for Cardiovascular Disease Prevention
Houston Methodist DeBakey Heart and Vascular Center
Steven E. Nissen, MD, MACC
Professor of Medicine
The Cleveland Clinic School of Medicine
Cleveland Clinic Main Campus
Robert P. Giugliano, MD
Physician, CV Medicine
Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medicial School
James Underberg, MD
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
President-Elect National Lipid Association
New York, NY
Disclosure of Conflicts of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Christie M. Ballantyne, MD||Consultant/Advisor: Abbott Laboratories; Amarin Corp.; Amgen, Inc.; AstraZeneca; Eli Lilly and Company; Esperion Therapeutics, Inc.; Genzyme Corporation; Ionis Pharmaceuticals; Matinas BioPharma Holdings, Inc.; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Diagnostics; Sanofi-Synthelabo, Inc.Grant/Research Support: Abbott Laboratories; Amarin Corp.; Amgen, Inc.; Eli Lilly and Company; Esperion Therapeutics, Inc.; Novartis AG; Pfizer Inc.; Otsuka America Pharmaceutical, Inc.; Regeneron Pharmaceuticals, Inc.; Roche Diagnostics; sanofi-aventis U.S. LLC.; Takeda Pharmaceuticals U.S.A., Inc.|
|Christopher P. Cannon, MD||Consultant/Advisor: Alnylam; Amgen, Inc.; Arisaph Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline plc.; Kowa Pharmaceuticals America, Inc.; LipoMedix; Merck & Co., Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.Grant/Research Support: Arisaph Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Company; GlaxoSmithKline plc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Takeda Pharmaceuticals U.S.A., Inc.|
|Robert P. Giugliano, MD, SM||Consultant/Advisor: Amarin Corp.; American College of Cardiology Foundation; Amgen, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVS/caremark; Daiichi Sankyo, Inc.; GlaxoSmithKline plc.; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Portola Pharmaceuticals, Inc.; Pfizer Inc.; St. Jude Children’s Research Hospital; Stealth BioTherapeutics Inc.Grant/Research Support: Amgen, Inc.Speakers Bureau: Amgen, Inc.; Daiichi Sankyo, Inc.; Merck & Co., Inc.|
|Steven E. Nissen, MD, MACC||Grant/Research Support: Amgen, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eli Lilly and Company; Novartis AG; Novo Nordisk A/S; Orexigen Therapeutics, Inc.; Pfizer Inc.; Resverlogix Corp.; Hoffmann-La Roche Ltd; Omthera Pharmaceuticals, Inc.; Sanofi; Southern Australian Health and Medical Research Institute (SAHMRI); Takeda Pharmaceuticals U.S.A., Inc.; The Medicines Company; VIVUS Inc.|
|James A. Underberg, MD||Consultant/Advisor: Aegerion Pharmaceuticals Inc.; Akcea Therapeutics; Amarin Corp.; Amgen, Inc.; Invitae Corporation; National Lipid Association.; Recombine;Grant/Research Support: Pfizer Inc.; Aegerion Pharmaceuticals Inc.Speaker’s Bureau: Alexion Pharmaceuticals, Inc.; Amgen Inc.; AstraZeneca; Genzyme Corporation; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; True Health Diagnostics|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Gilmartin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Amgen, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen, Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact firstname.lastname@example.org.
Provided by AcademicCME